News Headlines Article

Peninsula biotech sinks on two cancer failures
San Francisco Business Times

Threshold Pharmaceuticals Inc. lost more than 80 percent of its value Monday after announcing poor results from two late-stage studies of its headliner drug against two types of cancer. Evofosfamide didn’t improve over survival in combination with the chemotherapy gemcitabine in a group of patients with pancreatic cancer and failed when combined with the chemotherapy doxorubicin to help patients live longer with a type of cancers known as soft tissue sarcomas, which grow quickly after starting in muscle, fat or blood vessels.

Commands